Candel Therapeutics, Inc. (CADL): Price and Financial Metrics
GET POWR RATINGS... FREE!
CADL Stock Price Chart Interactive Chart >
CADL Price/Volume Stats
| Current price | $4.25 | 52-week high | $14.78 |
| Prev. close | $3.78 | 52-week low | $3.02 |
| Day low | $3.63 | Volume | 7,800 |
| Day high | $4.25 | Avg. volume | 46,658 |
| 50-day MA | $4.33 | Dividend yield | N/A |
| 200-day MA | $6.95 | Market Cap | 121.95M |
Candel Therapeutics, Inc. (CADL) Company Bio
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.
Latest CADL News From Around the Web
Below are the latest news stories about Candel Therapeutics Inc that investors may wish to consider to help them evaluate CADL as an investment opportunity.
Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific OfficerNEEDHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Francesca Barone, M.D., Ph.D., has been named as the company’s Chief Scientific Officer. Dr. Barone brings more than 20 years of experience in immunology, experimental medicine, and innovative drug development to help bring important new therapeutics to the clinic. Dr. Barone was previous |
What Percentage Of Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Do Insiders Own?If you want to know who really controls Candel Therapeutics, Inc. ( NASDAQ:CADL ), then you'll have to look at the... |
Candel Therapeutics to Present at Two Upcoming Investor ConferencesNEEDHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at the following virtual investor conferences in January: H.C. Wainwright BioConnect ConferenceFormat: Pre-recorded corporate presentationDate/Time: January 10, 2022, on-demand |
Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral ImmunotherapiesLOS ANGELES and NEEDHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Bionaut Labs, a company focused on revolutionizing the treatment of central nervous system disorders (CNS) with its Bionaut precision medicine treatment modality, and Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical-stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced a strategic collaboration to investigate the use of Bionauts remote-controlled microscale robots for precision delivery of Candels oncolytic viral immunotherapy agents to specific brain tumors. |
Candel Therapeutics and Partnership for Accelerating Cancer Therapies (PACT) to Collaborate on Lung Cancer Trial for CAN-2409Partnership for Accelerating Cancer Therapies to conduct extensive biomarker analysis for ongoing phase 2 clinical trial in non-small cell lung cancerTrial combines CAN-2409 with immune checkpoint inhibitor treatment after inadequate tumor response to initial checkpoint inhibitor therapyCollaboration may identify early markers of response and inform patient selection for treatment NEEDHAM, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage bi |
CADL Price Returns
| 1-mo | 18.72% |
| 3-mo | 3.16% |
| 6-mo | -58.98% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -45.65% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...